non glp-1 weight loss drugs Half of users ditch their injections — and some are turning to other weight-loss methods instead Chart: 1 in 8 Americans

this does not establish efficacy or long-term safety

Maiti A, Kantarjian HM, Popat V, Garcia-Manero G, Konopleva, M, Verstovsek S, Andreeff M , Borthakur G, Kadia T, Daver N, Pemmaraju N, DiNardo C, Pierce S, Wierda W, Kornblau S, Ravandi F, Cortes JE

The C rating comparison depends heavily on the specific cell model and chemistry

Szwed M, Marczak A

The phase IIb clinical trial studying danuglipron twice daily in participants with obesity had over 50% of patients discontinue treatment in comparison to about 40% with placebo

Eli Lilly stock (LLY) popped by more than 5% on Wednesday after the Food and Drug Administration (FDA) approved the company's new weight-loss pill that Eli Lilly says can be taken "any time of day without food or water restrictions." The approval sets up a new phase of competition between Eli Lilly and its main competitor, Danish drugmaker Novo Nordisk (NVO), in the weight-loss drug space